Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

[1]  Christopher M. Thompson,et al.  Isolation of Intact, Whole Mouse Mammary Glands for Analysis of Extracellular Matrix Expression and Gland Morphology. , 2017, Journal of visualized experiments : JoVE.

[2]  J. Pober,et al.  Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells , 2017, Nature Communications.

[3]  N. Williams,et al.  CO2 Capture from Ambient Air by Crystallization with a Guanidine Sorbent. , 2017, Angewandte Chemie.

[4]  Jing Wang,et al.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer , 2016, Modern Pathology.

[5]  John J Rossi,et al.  RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? , 2016, Annual review of pharmacology and toxicology.

[6]  Xiongbin Lu,et al.  A Near‐Infrared Laser‐Activated “Nanobomb” for Breaking the Barriers to MicroRNA Delivery , 2016, Advanced materials.

[7]  Xiongbin Lu,et al.  A Near-Infrared Laser-Activated "Nanobomb" for Breaking the Barriers to MicroRNA Delivery. , 2016, Advanced materials.

[8]  Xiongbin Lu,et al.  Nanoparticle systems reduce systemic toxicity in cancer treatment. , 2016, Nanomedicine.

[9]  Xiongbin Lu,et al.  Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. , 2015, Biomaterials.

[10]  Mark E. Davis,et al.  Clinical experiences with systemically administered siRNA-based therapeutics in cancer , 2015, Nature Reviews Drug Discovery.

[11]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[12]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[13]  T. Paull Mechanisms of ATM Activation. , 2015, Annual review of biochemistry.

[14]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[15]  Xiongbin Lu,et al.  Abstract A36: TP53 loss creates therapeutic vulnerability in colorectal cancer , 2017 .

[16]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[17]  D. Bulavin,et al.  Wip1 phosphatase in breast cancer , 2014, Oncogene.

[18]  A. Sood,et al.  The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. , 2014, Cell reports.

[19]  Daniel G. Anderson,et al.  In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. , 2014, Nature nanotechnology.

[20]  Neysa Nevins,et al.  Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction. , 2014, Nature chemical biology.

[21]  Cecil Han,et al.  Noncoding RNAs in DNA repair and genome integrity. , 2014, Antioxidants & redox signaling.

[22]  R. Losick,et al.  Synthesis and Activity of Biomimetic Biofilm Disruptors , 2013, Journal of the American Chemical Society.

[23]  F. Fuller-Pace,et al.  The RNA helicase p68 (DDX5) is selectively required for the induction of p53-dependent p21 expression and cell cycle arrest after DNA damage , 2012, Oncogene.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[25]  R. Losick,et al.  Synthesis and Activity of Biomimetic Bio fi lm Disruptors , 2013 .

[26]  D. Zardavas,et al.  Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer , 2012, Current opinion in oncology.

[27]  Myriam Gorospe,et al.  MS2-TRAP (MS2-tagged RNA affinity purification): tagging RNA to identify associated miRNAs. , 2012, Methods.

[28]  Bruce Stillman,et al.  DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. , 2012, Cancer discovery.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[30]  H. Stern Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges , 2012, Science Translational Medicine.

[31]  Munish Kumar,et al.  Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis , 2011, Proceedings of the National Academy of Sciences.

[32]  M. Jackson,et al.  TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells , 2011, Proceedings of the National Academy of Sciences.

[33]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[34]  Zhang,et al.  Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling Pathway , 2010 .

[35]  M. Smalley Isolation, culture and analysis of mouse mammary epithelial cells. , 2010, Methods in molecular biology.

[36]  C. Perou,et al.  Mammary development meets cancer genomics , 2009, Nature Medicine.

[37]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[38]  Hiroshi I. Suzuki,et al.  Modulation of microRNA processing by p53 , 2009, Nature.

[39]  N. Sharpless,et al.  p38MAPK controls expression of multiple cell cycle inhibitors and islet proliferation with advancing age. , 2009, Developmental cell.

[40]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[41]  D. Bartel MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[42]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Yolanda F. Darlington,et al.  The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways , 2008, Cancer and Metastasis Reviews.

[44]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[45]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[46]  E. Appella,et al.  The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis , 2007, Oncogene.

[47]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.

[48]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[49]  Romayne A. Thompson,et al.  Age-related lobular involution and risk of breast cancer. , 2006, Journal of the National Cancer Institute.

[50]  L. Donehower,et al.  Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice , 2006, Molecular carcinogenesis.

[51]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[52]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[53]  K. Hunt,et al.  Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells. , 2004, Surgery.

[54]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[55]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[56]  K. Gelmon,et al.  Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction , 2004, Clinical Cancer Research.

[57]  L. Donehower,et al.  Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.

[58]  K. Ang,et al.  Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.

[59]  Y. Shiloh ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[60]  Jeffrey R. Marks,et al.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.

[61]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[62]  Lawrence A. Donehower,et al.  Mice Deficient for the Wild-Type p53-Induced Phosphatase Gene (Wip1) Exhibit Defects in Reproductive Organs, Immune Function, and Cell Cycle Control , 2002, Molecular and Cellular Biology.

[63]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[65]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.